1. Home
  2. NEWT vs TECX Comparison

NEWT vs TECX Comparison

Compare NEWT & TECX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NewtekOne Inc.

NEWT

NewtekOne Inc.

HOLD

Current Price

$11.23

Market Cap

300.3M

Sector

Finance

ML Signal

HOLD

Logo Tectonic Therapeutic Inc. Common Stock

TECX

Tectonic Therapeutic Inc. Common Stock

HOLD

Current Price

$20.98

Market Cap

359.0M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
NEWT
TECX
Founded
1998
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
300.3M
359.0M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
NEWT
TECX
Price
$11.23
$20.98
Analyst Decision
Hold
Strong Buy
Analyst Count
4
5
Target Price
$13.25
$81.20
AVG Volume (30 Days)
197.6K
407.9K
Earning Date
10-29-2025
11-06-2025
Dividend Yield
6.80%
N/A
EPS Growth
32.88
N/A
EPS
2.23
N/A
Revenue
$380,364,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$12.56
N/A
P/E Ratio
$5.01
N/A
Revenue Growth
20.21
N/A
52 Week Low
$9.12
$13.70
52 Week High
$14.50
$61.07

Technical Indicators

Market Signals
Indicator
NEWT
TECX
Relative Strength Index (RSI) 65.98 59.16
Support Level $9.59 $18.60
Resistance Level $11.33 $22.00
Average True Range (ATR) 0.29 1.72
MACD 0.18 0.09
Stochastic Oscillator 94.25 78.88

Price Performance

Historical Comparison
NEWT
TECX

About NEWT NewtekOne Inc.

NewtekOne Inc is a financial holding company engaged in providing financial solutions to its Client Base. It is an internally managed non-diversified closed-end management investment company. It has four reportable segments Banking, Alternative Lending, Technology, NSBF, and Payments.

About TECX Tectonic Therapeutic Inc. Common Stock

Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.

Share on Social Networks: